Chinese Government Takes First Steps To De-link Indigenous Innovation And Procurement, But Industry Groups Wary
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Months after pledging a policy change, China is finally taking steps to break ties between indigenous innovation and government procurement policies. The changes in policy, according to a report released by the U.S.-China Business Council, address growing concern among multinationals that procurement policies - an estimated $1 trillion market - are increasingly designed to shut them out
You may also be interested in...
Rising Labor Cost Top Risk For Multinationals In China – AmCham Survey
A slowing economy and regulatory uncertainty loom large for multinationals operating in China. However, companies say rising labor costs impact them more, and acute shortages of qualified employees further complicate the landscape.
A Weak Link: Chinese Courts Reluctant To Grant Preliminary Injunctions In Pharma IP Cases
With a large number of pharma patents about to expire in China, hurdles to obtaining injunctive relief could be a huge problem, according to the EU Chamber of Commerce in China.
A Weak Link: Chinese Courts Reluctant To Grant Preliminary Injunctions In Pharma IP Cases
With a large number of pharma patents about to expire in China, hurdles to obtaining injunctive relief could be a huge problem, according to the EU Chamber of Commerce in China.